Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

ClinicalTrials.gov ID: NCT00073177

Public ClinicalTrials.gov record NCT00073177. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 24 Week, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Roflumilast (250 mcg or 500 mcg) Daily in Patients With Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The aim of the study is to compare the effects of oral roflumilast with placebo on lung function in patients with asthma.

Study identification

NCT ID
NCT00073177
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
819 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2003
Primary completion
Not listed
Completion
Not listed
Last update posted
Oct 24, 2016

Started 2003

United States locations

U.S. sites
37
U.S. states
37
U.S. cities
37
Facility City State ZIP Site status
ALTANA Pharma Cities in Alabama Alabama
ALTANA Pharma Cities in Arizona Arizona
ALTANA Pharma Cities in Arkansas Arkansas
ALTANA Pharma Cities in California California
ALTANA Pharma Cities in Colorado Colorado
ALTANA Pharma Cities in Florida Florida
ALTANA Pharma Cities in Georgia Georgia
ALTANA Pharma Cities in Idaho Idaho
ALTANA Pharma Cities in Illinois Illinois
ALTANA Pharma Cities in Indiana Indiana
ALTANA Pharma Cities in Iowa Iowa
ALTANA Pharma Cities in Kansas Kansas
ALTANA Pharma Cities in Kentucky Kentucky
ALTANA Pharma Cities in Louisiana Louisiana
ALTANA Pharma Cities in Maryland Maryland
ALTANA Pharma Massachusetts Massachusetts
ALTANA Pharma Cities in Michigan Michigan
ALTANA Pharma Cities in Minnesota Minnesota
ALTANA Pharma Cities in Mississippi Mississippi
ALTANA Pharma Cities in Missouri Missouri
ALTANA Pharma Cities in Montana Montana
ALTANA Pharma Cities in Nebraska Nebraska
ALTANA Pharma Cities in Nevada Nevada
ALTANA Pharma Cities in New Jersey New Jersey
ALTANA Pharma Cities in New York New York
ALTANA Pharma Cities in North Carolina North Carolina
ALTANA Pharma Cities in North Dakota North Dakota
ALTANA Pharma Cities in Oregon Oregon
ALTANA Pharma Cities in Pennsylvania Pennsylvania
ALTANA Pharma Cities in Rhode Island Rhode Island
ALTANA Pharma Cities in South Carolina South Carolina
ALTANA Pharma Cities in Tennessee Tennessee
ALTANA Pharma Cities in Texas Texas
ALTANA Pharma Cities in Utah Utah
ALTANA Pharma Cities in Virginia Virginia
ALTANA Pharma Cities in Washington Washington
ALTANA Pharma Cities in Wisconsin Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00073177, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 24, 2016 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00073177 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →